Evidence map›Paper›PMID 41168780›Full record

ArticleChinese medicine2025

Yiqi Wenyang Formula ameliorates diabetic kidney disease via inhibiting inflammation and regulating the gut microbiota-bile acid axis in mice by FXR signaling pathway.

Tongyi Yuan, Xiang Gao, Xinxin Wang, Xiaolei Tang, Zuguo Liang, Yifei Yin, Songyan Liu, Jianze Ou, Wenjie Su, Zepeng Zhang and 4 more

Abstract read
In one paragraph

Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Tongyi Yuan *Research Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130021, China.
Xiang Gao *Research Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130021, China.
Xinxin WangResearch Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130021, China.
Xiaolei TangResearch Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130021, China.
Zuguo LiangResearch Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130021, China.
Yifei YinResearch Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130021, China.
Songyan LiuResearch Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130021, China.
Jianze OuResearch Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130021, China.
Wenjie SuNortheast Asia Research Institute of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China.
Zepeng ZhangResearch Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130021, China.
Xiangyan LiNortheast Asia Research Institute of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China.
Qingxia HuangResearch Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130021, China. hqx19890928@163.com.
Daqing ZhaoNortheast Asia Research Institute of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China. zhaodaqing1963@163.com.
He ZhangResearch Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, 130021, China. 13843148162@163.com.

Funding

Innovation and Entrepreneurship Talent Funding Project of Jilin Province 2022ZY10National Natural Science Foundation of China 82405364Science and Technology Development Plan Project of Jilin Province 20210304001YYWellcome Trust 202320
6 · The paper itself

Abstract

backgroundDiabetic kidney disease (DKD) is a microangiopathic complication of diabetes. Yiqi Wenyang Formula (YQWYF) has been used to treat DKD in the clinic for many years. However, the underlying regulatory mechanisms of YQWYF on the gut microbiota and bile acids of DKD mice remain unclear. PURPOSE OF THE RESEARCH: This study aimed to investigate the mechanism of YQWYF on DKD mice using an integrative approach of network pharmacology, fecal 16S ribosomal RNA (rRNA) gene sequencing, and untargeted metabolomics.

methodsThe chemical composition of YQWYF was determined via ultrahigh-performance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS). Common targets were identified between YQWYF and DKD, and a potential protein-protein interaction (PPI) network was constructed using network pharmacology. DKD mice were induced with streptozotocin (STZ) for 18 weeks. Twenty-four-hour urine was collected on the 9th and 18th weeks, and serum was collected on the 18th week to detect the biochemical measurements of urine and serum. Oxidative stress biomarkers and inflammatory cytokines in the kidney were detected via ELISA kits. The microstructure of the renal tissue was assessed by hematoxylin-eosin staining, periodic-acid Schiff staining, and Masson staining. Fresh fecal sample of mice were collected on the 18th week to detect the gut metabolites and microbiota using untargeted metabolomics and 16S rRNA sequencing. We analyzed the gut microbiota-bile acid (BA) axis for mechanism exploration.

resultsA total of 41 compounds were recognized in YQWYF. TNF and IL6 were the important core targets between YQWYF and DKD. The results of molecular docking revealed that astragaloside I, 16-meprednisone acetate, and astragaloside IV from YQWYF had strong affinities for TNF-α and IL-6. Animal experiments showed that YQWYF reduced glycemia and improved lipid metabolism abnormalities in DKD mice. Moreover, it had excellent anti-oxidant and anti-inflammatory effects to ameliorate renal injury in DKD mice. YQWYF improved the richness and evenness of the gut microbiota and increased bile acid levels in the feces of DKD mice. Importantly, 4 genus bacteria (christensenellaceae_R-7_group, oscillibacter, UCG-005, and [Eubacerium]_ xylanophilum_group) were closely related with 3 BAs (CA, GCA and DHCA). Meanwhile, YQWYF improved the protein expression of Farnesoid X receptor (FXR), CYP7A1 and CYP8B in the liver.

conclusionThese findings reveal that YQWYF ameliorates renal injury in DKD mice by inhibiting the inflammatory, increasing the FXR signaling, and regulating the gut microbiota disorder and bile acid dysregulation.

Indexed as

Bile aciddiabetic kidney diseaseFXRgut microbiotaMolecular dockingYiqi Wenyang Formula

Identifiers

PMID41168780
PMCPMC12574177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.